Annovis Bio to Present Comprehensive Buntanetap Data at Parkinson Study Group Meeting

Annovis Bio Inc. (NYSE: ANVS), a late-stage clinical drug platform company developing therapies for neurodegenerative diseases, will present new findings about its investigational drug buntanetap at the 2025 Annual Meeting of the Parkinson Study Group in San Diego. The presentation will expand on recent Phase 3 Parkinson's biomarker results, revealing that patients with amyloid co-pathology experience more severe cognitive decline that appears to be reversed by buntanetap treatment.

The data to be presented indicates buntanetap not only addresses cognitive symptoms but also reduces tau biomarkers linked to disease progression in Parkinson's disease. This dual effect on both cognitive function and underlying disease pathology represents a significant development in neurodegenerative research. The company will also debut a cross-study comparison of all completed trials, offering what it describes as the most comprehensive view to date of cognitive outcomes across different indications.

This comprehensive analysis underscores that patients with amyloid pathology achieve the greatest cognitive benefit from buntanetap treatment, supporting Annovis Bio's strategic path forward in drug development. The findings have important implications for treatment approaches in both Parkinson's and Alzheimer's diseases, suggesting that targeting specific pathological markers may yield more effective therapeutic outcomes. For more information about the company's research, visit https://www.annovisbio.com.

The presentation at the Parkinson Study Group meeting represents a significant milestone in understanding how buntanetap affects different patient populations. By identifying which patients benefit most from treatment, researchers can better target future clinical trials and potentially develop more personalized treatment approaches for neurodegenerative diseases. The reduction of tau biomarkers is particularly noteworthy, as tau pathology is associated with disease progression in multiple neurodegenerative conditions.

These findings come at a critical time for neurodegenerative disease research, as the medical community seeks more effective treatments for conditions affecting millions worldwide. The ability to reverse cognitive decline in patients with specific pathological markers represents a promising direction for future therapeutic development. The latest news and updates relating to ANVS are available in the company's newsroom at https://ibn.fm/ANVS.

The implications of these findings extend beyond Parkinson's disease to other neurodegenerative conditions where amyloid and tau pathology play significant roles. By demonstrating differential treatment effects based on underlying pathology, the research may help guide more targeted approaches to drug development across multiple neurodegenerative diseases. This could potentially lead to more effective treatments that address the specific pathological mechanisms driving different forms of cognitive decline.